We invent novel drugs for patients with cancer and autoimmune disease.

As you’ll see throughout this website, we have invented and advanced a number of interesting drug candidates through preclinical development with two now in the clinic. There is no “me too” drug candidate in our portfolio. Cancer and autoimmune disease patients need us to be creative and focused on novel scientific approaches.

Our special sauce is that our team is small and nimble. We are efficient. We collaborate.

We partner with highly skilled people outside the company, both in academia and industry, who keep advancing our collective technical level. Colleagues who visit Gliknik tend to be surprised by the number of compounds we make and the number of products we are advancing. When we stumble, which is an inevitability in this industry, we persevere until we get it right. Most importantly, we have pursued our business in a manner consistent with our core values with integrity being first and foremost.

We are resolved to make a difference for individuals living with cancer or autoimmune diseases and are thankful for the confidence entrusted in us by our investors.

David S. Block
CEO, Gliknik Inc.